BTK Inhibitors for CLL
Clinical Pearls and Future Directions
CHICAGO, ILLINOIS - Fairmont Chicago, Millennium Park
September 7, 2019 | 7:00 pm
    Activity Overview

    Effective management of patients with chronic lymphocytic leukemia (CLL) includes treatment that is individualized based on patient- and disease-specific factors. The introduction of Bruton's tyrosine kinase (BTK) inhibitors into the treatment paradigm for CLL has greatly improved patient outcomes. However, challenges related to resistance, intolerance, and treatment-related adverse effects can lead to discontinuation of therapy and suboptimal outcomes for some patients. Next-generation BTK inhibitors such as acalabrutinib may offer benefit over ibrutinib, and combination treatment strategies are also being explored to improve efficacy and safety.

    This interactive symposium is designed to improve knowledge of hematologists/oncologists about the latest data on use of BTK inhibitors for the treatment of CLL. A focus of the symposium will be clinical pearls from experts that will aid clinicians with integrating the data into clinical practice. iPads will allow interaction with the experts through polling questions and the ability to ask questions throughout the program.

    • Farrukh T. Awan, MD
    • Farrukh T. Awan, MD
      Associate Professor of Medicine
      Director of Lymphoid Malignancies Program
      University of Texas Southwestern
      Dallas, Texas
    • John N. Allan, MD
    • John N. Allan, MD
      Assistant Professor of Medicine
      Division of Hematology and Medical Oncology
      Weill Cornell Medical College
      New York, New York
    Program Saturday, September 7, 2019
    • 7:00 PM
    • Registration and Dinner
    • 7:15 PM
    • Welcome and Introductions
      Farrukh T. Awan, MD
    • 7:20 PM
    • Differentiating Among First- and Next-Generation BTK Inhibitors
      Farrukh T. Awan, MD
    • 7:30 PM
    • The Role of BTK Inhibitors for Previously Untreated CLL
      John N. Allan, MD
    • 7:45 PM
    • Managing Previously Treated CLL With BTK Inhibitors
      Farrukh T. Awan, MD
    • 8:00 PM
    • Potential Adverse Events of BTK Inhibitors
      Farrukh T. Awan, MD
    • 8:15 PM
    • Future Directions
      John N. Allan, MD
    • 8:25 PM
    • Summary and Conclusions
      Farrukh T. Awan, MD
    • 8:35 PM
    • Panel Discussion and Q&A
      Farrukh T. Awan, MD and John N. Allan, MD
    Learning Objectives
      • Differentiate between the selectivity and adverse effects of first- and next-generation BTK inhibitors used to treat CLL
      • Describe features of a patient with previously untreated CLL that would make them a suitable candidate for a next-generation BTK inhibitor
      • Discuss the role of first- and next-generation BTK inhibitors in the management of previously treated CLL
      • Apply best practices for managing treatment-related adverse effects of BTK inhibitors
    Target Audience
    Goal Statement
    Association Disclaimer Statement
    Credits Available
    • 1.50
    • For Physicians
    Accreditation Statement
    Fairmont Chicago, Millennium Park
    Room: Rouge
    Supported by an independent educational grant from
    Acerta Pharma - A member of the AstraZeneca Group.